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ABSTRACT
Cytomegalovirus (CMV) infection is one of the most important infectious complications of solid-organ
transplantation, and is also responsible for serious, life-threatening diseases in patients infected with
human immunodeﬁciency virus (HIV). Tremendous progress has been made with respect to prevention
and treatment of CMV disease in such patients. The use of anti-CMV drugs and the immune
reconstitution achieved by use of anti-retroviral drugs has reduced the incidence of CMV disease
dramatically. Nevertheless, problems of clinical relevance remain (e.g., drug toxicity, drug–drug
interactions, antiviral resistance) and new problems have emerged. Intragenic recombination among
different CMV strains has been identiﬁed as a possible source of novel CMV strains in patients with
advanced HIV infection. Development of a protective CMV vaccine remains elusive, perhaps, in part,
because of strain-speciﬁc variation in immunodominant epitopes. Late-onset CMV disease, which
occurs several months or years after transplantation, has been recognised as a clinically relevant
complication in transplant recipients. The most effective strategy for the prevention of CMV disease in
transplant recipients (i.e., prophylaxis or pre-emptive therapy) remains a matter of debate. A link
between CMV infection and Guillain–Barre´ syndrome, a neurological disease characterised by ﬂaccid
paralysis, has been substantiated, but the efﬁcacy of antiviral therapy in such patients remains to be
determined. This review summarises the current status of CMV disease in immunocompromised
patients, and discusses some of the emerging issues of clinical relevance with regard to CMV infection in
patients with disorders of the immune system.
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CYTOMEGALOVIRUS INFECTION
Cytomegalovirus (CMV) is a member of the
b-herpes-virus group and is characterised by its
strict species speciﬁcity, long life-cycle, and life-
time persistence within the host [1]. CMV is
transmitted via saliva, sexual contact, placental
transfer, breast-feeding, blood transfusion and
solid-organ or haematopoietic stem-cell trans-
plantation. After entry, the virus disseminates
within the host; this is probably facilitated by
leukocytes. Productive infection resolves sponta-
neously in the normal host, after which CMV
establishes life-long latency or persistence within
the infected individual. In the developed world,
acquisition of CMV occurs progressively from
an early age, with an overall seroprevalence of
c. 60% [2]. Thus, a large proportion of the adult
population remains susceptible to primary infec-
tion in developed countries. In contrast, homo-
sexual men, poor socio-economic groups and
residents of developing countries have seroprev-
alence rates of >90% [3,4].
Reactivation from latency is indicated by
viraemia or shedding of CMV in various body
ﬂuids, including saliva, urine, tears, semen,
cervicovaginal ﬂuid and breast milk. Periods of
virus shedding in urine become less common
with increasing age of the infected individual,
although reactivation from latency is observed in
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13% of healthy adults [5]. The factors leading to
reactivation from latency are not completely
understood. In particular, production of the stress
hormones cortisol, adrenocorticotrophic hor-
mone, epinephrine and norepinephrine has been
implicated in the reactivation and shedding of
CMV in urine [6]. In healthy individuals, produc-
tive CMV infection is usually asymptomatic,
whereas immunocompromised patients may
develop CMV disease.
CMV INFECTION AND DISEASE IN
IMMUNOCOMPROMISED PATIENTS
CMV infection is one of the most important
infectious complications of solid-organ trans-
plantation [7], and is responsible for serious, life-
threatening diseases in patients infected with
human immunodeﬁciency virus (HIV) [8]. CMV
infection, deﬁned as a signiﬁcant rise in the titre
of CMV-speciﬁc antibodies, occurs in 44–85% of
kidney, heart and liver transplant recipients, com-
monly within the ﬁrst 3 months post-transplanta-
tion, when immunosuppression is most intense
[9,10]. Transplant patients with no pre-existing
CMV-speciﬁc immunity, i.e., CMV-seronegative
recipients (R–) of an organ from a CMV-seroposit-
ive donor (D+), and HIV-infected patients with a
CD4 cell count <100 ⁄ lL, are at highest risk forCMV
disease [11–13].
CMV disease manifests in the vast majority of
transplant recipients as a viral syndrome that
includes fever, malaise, myalgia or headache.
End-organ disease affects 10–30% of patients with
CMV disease [14,15], most commonly involving
the transplanted organ. Consecutive dissemin-
ation to and involvement of other organs, e.g., the
central nervous system, eye and the urogenital
or gastrointestinal tracts (Fig. 1), are observed
frequently [16]. In HIV-infected patients, retinitis
is the single most common manifestation of CMV
disease, accounting for 85% of all cases [8,12]. In
developing countries, CMV retinitis is still the
most frequent cause of visual loss in HIV-infected
patients [17].
Paradoxically, the reconstitution of the immune
response in HIV-infected patients can also have
detrimental effects. Following the introduction of
highly active anti-retroviral treatment (HAART),
an unusually high incidence of vitritis, an inﬂam-
mation of the eye chamber, has been noted. This
phenomenon of inﬂammatory complications of
immune reconstitution has collectively been
termed ‘immune reconstitution inﬂammatory
syndrome’, and is thought to represent the
response of the regenerating immune system to
persisting antigens, such as CMV [18–20].
In addition to causing symptomatic disease,
CMV employs multiple mechanisms to evade the
host’s innate and speciﬁc immunity [21]. The
clinical signiﬁcance of these in-vitro ﬁndings has
been demonstrated in multiple clinical studies. In
transplant recipients, CMV disease, as well as
CMV infection, were signiﬁcant independent
predictors of acute rejection of transplanted
organs [11,22] and reduced long-term graft
function [23,24]. Probable mechanisms are
CMV-induced up-regulation of vascular and
intercellular adhesion molecules, and endothelial
cell damage caused by alloreactive T-cells
[25,26]. Transplant rejection rates were reduced
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Fig. 1. Examples of cytomegalovirus (CMV) disease. (a)
CMV oesophagitis presenting as a large, shallow ulcer
with a punched-out border. CMV was demonstrated
immunohistochemically from a representative biopsy of
the ulcerated area (image kindly provided by M. Ha¨fner,
Medical University Vienna, Austria). (b) CMV retinitis in a
patient with AIDS appears as an arcuate zone of retinitis
with extensive haemorrhages and optic disk swelling
(image kindly provided by Dr Dejaco-Ruhswurm, Medical
University Vienna, Austria). (c, d) CMV ventriculoen-
cephalitis. Multiple small, peri-ventricular lesions of the
brain detected following brain magnetic resonance imag-
ing (arrows) (image kindly provided by M. Thurnher,
Medical University Vienna, Austria).
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signiﬁcantly by the use of antiviral prophylaxis
against CMV [27].
New-onset diabetes mellitus has been linked to
CMV infection in a cohort of kidney transplant
recipients [28]. In the case of active CMV infec-
tion, the net level of therapeutic immunosuppres-
sion is augmented in transplant patients, and the
susceptibility to a variety of other opportunistic
infections is increased in transplant recipients and
HIV-infected patients [7,29]. Finally, CMV disease
has been associated with accelerated cardiac
allograft vasculopathy in heart transplant recipi-
ents [30]. Among HIV-infected patients, those
who are CMV-seropositive progress 2.5-fold more
rapidly to AIDS and death than those who are
CMV-seronegative [31–33]. In the case of primary
CMV infection, even HIV-infected patients with a
relatively high CD4 cell count (>100 ⁄mm3) are at
signiﬁcantly increased risk for progression to
AIDS [34].
DECLINING INCIDENCE OF
CMV DISEASE IN
IMMUNOCOMPROMISED PATIENTS
Tremendous progress has been made in the
prevention and therapy of CMV disease among
transplant recipients and HIV-infected patients.
Apart from improvements in immunosuppressive
therapy, the control of CMV infection following
solid-organ transplantation has been considered
to be the most signiﬁcant advance in organ
transplantation to have taken place in the past
20 years [35]. CMV disease has become a rare
complication of organ transplantation, and the
effects that are associated indirectly with CMV
disease, namely rejection and opportunistic infec-
tion, have been reduced dramatically [36–38].
A meta-analysis of clinical trials evaluating the
use of ganciclovir revealed a reduction in the
development of CMV disease of 72–80% com-
pared with that of controls [39].
CMV infection was one of the most important
opportunistic infections in HIV-infected patients
before the introduction of HAART. Approxi-
mately 40% of HIV-infected patients with
advanced disease suffered from one of several
manifestations of CMV disease during their life
[40–43]. Although prophylaxis and treatment of
other AIDS-related opportunistic infections had
improved the overall prognosis and extended
the life-expectancy of HIV-infected patients
signiﬁcantly, the lifetime risk of CMV disease
had increased concomitantly shortly before the
introduction of HAART [44]. In 1995–1996, the
concept of combining at least three anti-retroviral
drugs of different classes (i.e., HAART) for the
treatment of HIV-infected patients was intro-
duced. Since then, HAART has increased
life-expectancy and quality of life dramatically,
with persistent suppression of HIV viraemia.
Overall HIV-related mortality decreased from
29.4 ⁄ 100 patient-years in 1994 to 8.8 ⁄ 100 patient-
years in 1997 [45]. In parallel with persistent
immune reconstitution, decreased CMV replica-
tion and a reduced incidence of CMV disease in
HIV-infected patients were observed [45–49].
Accordingly, the incidence of CMV retinitis,
which is the most common CMV disease among
HIV patients, decreased from 17.1 ⁄ 100 patient-
years to 5.6 ⁄ 100 patient-years [45,50].
CURRENT ISSUES IN THE
PREVENTION AND MANAGEMENT
OF CMV DISEASE
Considering the dramatic drop in the incidence of
CMV disease among transplant recipients and
HIV-infected patients, is it still necessary to be
concerned about this infection? Multiple factors
concerning the prevention and treatment of CMV
disease in immunocompromised patients have
remained highly relevant, including the toxicity
of antiviral drugs, antiviral resistance, drug–drug
interactions, patient adherence to treatment
regimens, availability of antiviral drugs in
resource-poor settings, and economic costs asso-
ciated with the use of antiviral drugs [17,51–59].
Moreover, selected groups of patients are still at
risk for CMV disease. For example, a considerable
number of HIV-infected patients have a CD4 cell
count below the critical threshold of 100 ⁄ lL, for
the simple reason that an increase in a CD4 cell
count to >100 ⁄ lL usually requires a period of
>6 months after initiation of HAART. In partic-
ular, patients are still at high risk of developing
CMV disease during the initial months of anti-
retroviral treatment and before full reconstitution
of cellular immunity [49,60–62]. In addition, CD4
cell counts remain <100 ⁄ lL in 10–20% of patients
treated with HAART [63], and a substantial
number of HIV-infected patients at risk for CMV
disease do not receive HAART because of non-
compliance or intolerance to prescribed regimens
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[64]. Additional challenges in the prevention and
treatment of CMV disease have emerged more
recently and may gain further in signiﬁcance. The
remainder of this review will focus on some of
these emerging challenges.
GENETIC DIVERSITY OF CMV
STRAINS AND EMERGENCE OF
NOVEL CMV GENOTYPES
The CMV genome is highly conserved and exhib-
its low genetic variation. Clinical and laboratory
reference CMV strains (Towne and AD169) are
closely related at a genomic level, as indicated by
an overall DNA sequence homology of 90–95%
[65,66]. Electrophoretic patterns of virion or
infected-cell proteins from different strains are
similar, to the extent that differentiation among
strains is impossible using these tools [67,68].
Nevertheless, the more sensitive tools of restric-
tion site polymorphism analysis [69] and sequence
analysis by PCR have allowed the differentiation
of distinct CMV genotypes by analysis of more
variable regions of the CMV genome [70,71]. A
large number of CMV strains are apparently in
circulation worldwide, and these have different
geographical frequency distributions [72]. Based
on an analysis of nine genomic sites, it has become
apparent that, in theory, a virtually inﬁnite num-
ber of CMV strains may exist [72].
Variation in CMV genes translates into multiple
strain-speciﬁc epitopes on different viral proteins
[73]. Antibodies produced against one CMV strain
generally react with other strains, but in the case of
CMV infection with a different strain (re-infec-
tion), strain-speciﬁc immunity confers little cross-
protection [74]. Although there is considerable
interest in developing a CMV vaccine, and several
candidates are in development, attempts have not
succeeded to date. Single candidate proteins
include glycoprotein B (gB) (with the aim of
inducing neutralising antibody) and the pp65
tegument protein (with the aim of inducing a
strong cytotoxic T-lymphocyte (CTL) response)
[75]. An intact live virus vaccine approach is also
being pursued, using recombinant virus produced
from strain AD169 and the Toledo isolate, which is
closer to clinical isolates in its tropism and genetic
structure [76]. Results in rodent models have been
very promising. In clinical trials using single
protein as well as intact virus vaccines, neutral-
ising antibodies and detectable CMV-speciﬁc
cellular immunity could be induced [77–79].
However, to date, none of the vaccines evaluated
in larger cohorts has provided reliable protection
against CMV infection [80,81]. The variation in
immunogenic epitopes among clinical CMV
strains may explain some of the disappointing
clinical results obtained with CMV vaccine candi-
dates. Laboratory strains used for vaccine design
may differ signiﬁcantly from clinical strains, in
terms of antigenic epitopes, and some clinical
strains may be very difﬁcult to culture.
Subtype classiﬁcation of CMV strains has been
based most frequently on the gB gene (UL55) [82].
Glycoprotein B plays an important role in cell-to-
cell transmission [83], is a major functional region
promoting virion entry, as well as cell-to-cell
spread of infection and fusion [84,85], and is a
major target of neutralising antibodies [86]; thus,
it has been considered to be a prime candidate for
a CMV vaccine. Four major gB subtypes, with
different geographical frequency distributions,
have been characterised to date [82,87]. However,
co-infection with more than one CMV strain is not
unusual, and primary CMV infection with several
CMV strains simultaneously has been observed in
immunocompetent individuals [88]. An analysis
of CMV strain-speciﬁc antibodies has revealed
that exposure to multiple CMV strains may occur
in c. 20% of the healthy population [89].
Co-infection with different CMV strains is also
of clinical relevance. Humar et al. [90] demonstrat-
ed that infections with mixed CMV gB-subtype
strains in solid-organ transplantation may be
associated with delayed clearance of the virus
from blood during therapy. This ﬁnding is of
special interest, as delayed virus clearance during
receipt of antiviral therapy may also signify a
higher risk of development of drug resistance. In
another study, mixed gB-subtype infections were
associated with increased graft rejection and
disease progression [91].
HIV-infected patients are co-infected with dif-
ferent CMV strains even more frequently than the
general population [92], and often with more than
one CMV gB subtype [93]. Reactivation of CMV
is observed most frequently in patients with
advanced HIV infection and signiﬁcant immuno-
suppression [94]. There is also evidence of intra-
genic recombination as a source of novel CMV
strains in HIV-infected patients with severe
immunodeﬁciency [95]. The majority of CMV gB
strains detected in HIV-infected patients with
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CMV encephalitis differed signiﬁcantly from
those found in immunocompetent patients [95].
Previous studies have suggested that homologous
recombination contributes to the variability of the
gB gene, both in vitro and in vivo, and cell culture
experiments have demonstrated that co-infection
with two CMV strains may give rise to viable
recombinant CMV gB strains [96]. Co-infection by
several CMV strains might provide the basis for
CMV intragenic recombination and for the
emergence of CMV variants with altered biolo-
gical properties. The fact that CMV evades
immunity by mutations in immunodominant
domains may provide a signiﬁcant biological
advantage for CMV.
LATE-ONSET CMV DISEASE IN
SOLID-ORGAN TRANSPLANT
RECIPIENTS
Antiviral prophylaxis, i.e., the treatment of all
patients before the detection of CMV replication,
is highly effective in preventing CMV disease
in transplant recipients, particularly in R– ⁄D+
patients, who are at highest risk for CMV disease
[39]. However, prophylaxis is also associated with
a considerable risk of increased toxicity and
antiviral drug resistance following prolonged
exposure to antiviral compounds. Late-onset
CMV disease has been recognised more recently
as a signiﬁcant complication of antiviral prophy-
laxis. Patients are protected during the period of
antiviral prophylaxis, but are at risk for CMV
disease thereafter. In the late transplantation
period, the level of immunosuppression is usually
less intense, and the incidence of CMV disease is
therefore clearly lower than during the early
transplantation period (i.e., before and after
6 months post-transplantation) [97]. Nevertheless,
late-onset CMV disease is observed increasingly,
and is far from trivial. Among kidney and
kidney–pancreas transplant recipients, late-onset
CMV disease was documented in 47% of R– ⁄D+
patients, 12% of R+ ⁄D+ patients, 7% of R+ ⁄D–
patients, and 4% of R– ⁄D– patients [98]. In a
cohort of haematopoietic stem-cell transplant
recipients, late-onset CMV disease occurred in
18% of patients, with a mortality rate of 46% in
these patients [99]. In addition, late-onset CMV
disease may have atypical manifestations, making
the evaluation of symptomatic patients even more
difﬁcult [100,101].
An increasing body of evidence suggests that
antiviral prophylaxis may even increase the risk
of late-onset CMV disease. Delayed recovery of
CMV-speciﬁc T-cell responses has been reported
in association with the administration of antiviral
drugs for prolonged periods [102]. Lack of recon-
stitution of CMV-speciﬁc cellular immunity in
transplant recipients has been a signiﬁcant factor
in the subsequent development of CMV disease in
haematopoietic stem-cell and solid-organ trans-
plant recipients [102]. Delayed recovery of the
virus-speciﬁc host response is not associated
uniquely with the use of ganciclovir, and has
also been observed following prolonged exposure
to other nucleoside antiviral agents and with
other herpes viruses [103]. Prolonged ganciclovir
prophylaxis in solid-organ transplant recipients
may interfere with the humoral immune response
[104], which is required to limit viral dissemin-
ation throughout the host [105]. Immunoglobulin
class-switching from IgM to IgG antibodies was
impaired, and antibody maturation was inhibited
in a subgroup of solid-organ transplant recipients
who received ganciclovir prophylaxis [104].
As an alternative, the concept of pre-emptive
therapy aims at suppression of viral replication
before the occurrence of CMV disease. This is
usually achieved by screening blood samples
routinely for the presence of CMV viraemia, with
the administration of a short course of antiviral
treatment in the case of a positive laboratory
result. Pre-emptive therapy is also highly effective
in preventing CMV disease [39]. A meta-analysis
of prospective, randomised trials involving solid-
organ transplant recipients revealed that the
overall reduction in risk of CMV-based organ
disease was comparable with pre-emptive therapy
(80%, 95% CI 53–90%) and prophylaxis (77%,
95% CI 65–85%) [39]. Nevertheless, the effects of
the two strategies on the occurrence of late-onset
CMV disease could not be evaluated, because of
the limited data available [39]. Thus, as both
strategies are highly effective in preventing CMV
disease, it remains unclear whether an individual
patient should receive prophylaxis or pre-emptive
therapy. This question has sparked an intense
discussion [35,106] that has also prompted an
indirect comparison of meta-analyses of the two
prevention strategies [107]. Prophylaxis and pre-
emptive therapy were similarly effective in pre-
venting CMV disease in general, but ineffective in
preventing CMV disease occurring >90 days after
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transplantation. However, comparison of the
two strategies, with respect to late-onset disease,
was based on only 22 and ﬁve cases, respectively
[107].
Direct comparisons of antiviral prophylaxis
against pre-emptive therapy have only involved
small trials, designed primarily to show equival-
ence of the two strategies in preventing CMV
disease [108,109]. Well-designed, direct-compar-
ison trials are urgently required to provide deﬁn-
itive data and to clarify whether prophylaxis or
pre-emptive therapy, or a combination of both, is
most effective in preventing early- and ⁄ or late-
onset CMV disease.
CMV INFECTION IN PATIENTS WITH
GUILLAIN–BARRE´ SYNDROME
Textbooks of clinical medicine describe several
diseases of unknown aetiology, but which have
features that suggest the possible role of virus
infections in their pathogenesis, e.g., Wegener’s
granulomatosis or Guillain–Barre´ Syndrome
(GBS). GBS has become the most frequent cause
of acute ﬂaccid paralysis in Western countries,
following the near-elimination of poliomyelitis.
The current annual incidence is estimated to be
0.75–2 cases ⁄ 100 000 population [110]. Good pro-
gress has been made in elucidating relevant
pathomechanisms and identifying effective thera-
peutic approaches, but understanding of the
mechanisms causing GBS is still very limited.
An increasing body of knowledge supports the
concept that GBS is the result of an aberrant
organ-speciﬁc immune response that may follow
triggering events [111,112]. Infectious agents have
been suggested as possible triggers of GBS, as
some form of respiratory or gastrointestinal infec-
tion precedes nearly two-thirds of GBS cases
[113].
Infection with CMV is the most common
antecedent virus infection, as identiﬁed by the
presence of IgM antibodies in 10–15% of patients
at the onset of GBS [114–116]. However, antiviral
therapy is currently not recommended in cases of
GBS, since the disease is considered to be post-
infectious. Recently, the presence of CMV DNA
has been demonstrated in almost one-third of
serum and cerebrospinal ﬂuid samples from GBS
patients who were positive for CMV-speciﬁc
antibodies at the onset of the neurological disease
[117]. Furthermore, the time of lumbar puncture
was critical for the detection of CMV DNA, as the
probability of the presence of CMV DNA de-
creased signiﬁcantly with an increasing interval
between the onset of GBS and the time of sample
collection. This association suggests that even
more patients may have been carrying CMV in
cerebrospinal ﬂuid at a very early stage of GBS.
Active CMV infection supports the link between
neurological disease and virus infection, but the
clinical relevance of this ﬁnding has still to be
elucidated.
Visser et al. [118] found that GBS patients with
CMV-speciﬁc IgM antibodies had clinical proﬁles
that differed from those without serological
evidence of a recent CMV infection. CMV IgM-
positive patients were younger, and had more
severe sensory abnormalities, more frequent facial
weakness, and a more frequent severe general
weakness that required artiﬁcial ventilation, with
a consequent delayed recovery. These ﬁndings
were conﬁrmed in a more recent study [119].
CMV-speciﬁc IgM antibodies are produced dur-
ing primary infection, but also during reactivation
and re-infection [112]. The mechanisms of patho-
genesis and the immunological consequences are
signiﬁcantly different in these two instances.
Following primary infection, CMV-speciﬁc anti-
bodies increase to high titres rapidly; however,
antibody avidity is initially low, and maturation
requires >1 year [105,120]. Molecular mimicry,
which has been proposed as a relevant mechanism
in the pathogenesis of GBS [113], and cross-reac-
tivity of CMV-speciﬁc antibodies with neuronal
structures, would be expected to be more likely in
primary CMV infection than during the course of
virus reactivation because of the lower antibody
speciﬁcity and antibody afﬁnity soon after infec-
tion. However, detectable CMV-speciﬁc IgM
antibodies in the presence of CMV-speciﬁc IgG
antibodies in a serum sample may not prove
primary infection, since IgM antibodies are also
produced during reactivation and re-infection
[112].
Primary CMV infection occurring within
6 months of the onset of GBS was found to be
common in CMV-seropositive patients [119].
Low-avidity IgG antibodies, which indicate an
immature immune response to a speciﬁc antigen
following recent primary exposure, were found in
20% of CMV-seropositive GBS patients [119].
However, 4% of GBS patients were positive
for CMV-speciﬁc IgM antibodies, but had IgG
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antibodies of high avidity, indicative of a
previous CMV infection. The presence of
CMV-speciﬁc IgM antibodies or CMV viraemia,
despite a previous CMV infection, might also be
explained by re-infection with a different CMV
genotype. It is well-known that CMV infection
confers little cross-protection against infection
with a different genotype [74]. Re-infection may
be associated more frequently than reactivation
with the presence of CMV viraemia or IgM
antibodies in serum, but cannot be detected with
currently available assays. Re-infection could also
explain why primary CMV infection has not been
associated with a more severe course of GBS.
CONCLUSIONS
Prevention and therapy of CMV disease remains a
clinical challenge, despite the availability of
highly effective antiviral and anti-retroviral
drugs. Antiviral drug resistance, toxicity, the
emergence of novel CMV genotypes with altered
biological properties, the development of a pro-
tective CMV vaccine and late-onset CMV disease
are all current topics of high clinical relevance.
The possible link between GBS and CMV infec-
tion requires further investigation. The clinical
signiﬁcance of such a link, and the consequences
with respect to patient management, remain to
be elucidated, with particular reference as to
whether GBS patients should receive antiviral
therapy. Nevertheless, the tremendous progress
during the past two decades in the prevention
and treatment of CMV disease justiﬁes optimism
for the future.
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